Core Insights - Altimmune (ALT) is advancing pemvidutide in the competitive field of metabolic dysfunction-associated steatohepatitis (MASH), emphasizing its dual glucagon/GLP-1 receptor agonist's potential for liver benefits and weight loss [1][10] - The year 2026 is pivotal for ALT, with a phase III MASH trial starting alongside significant data releases for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), amid increasing cash requirements and competition [2][10] Competitive Landscape - MASH is characterized as highly competitive, with ALT facing established metabolic franchises and well-funded biotech peers [3] - Major competitors include GLP-1 drugs from Novo Nordisk and Eli Lilly, as well as MASH-focused developers like Madrigal Pharmaceuticals and Viking Therapeutics [4][5] Differentiation Strategy - Pemvidutide's mechanism combines glucagon and GLP-1 activity, targeting liver fat reduction and inflammation while promoting weight loss [6] - The drug's tolerability is enhanced through EuPort technology, which aims to minimize gastrointestinal side effects, potentially leading to longer treatment adherence [7] Clinical Development Plans - ALT plans to initiate a global phase III MASH program in 2026, targeting patients with moderate-to-severe liver fibrosis, with a focus on accelerated approval based on week 52 biopsy endpoints [9][10] - The study will involve approximately 1,800 patients, with dosing strategies aligned to previously established levels [10][11] Broader Pipeline and Catalysts - ALT is also conducting mid-stage studies in AUD and ALD, with significant unmet needs and commercial potential [12] - The phase II RECLAIM study for AUD is expected to yield top-line data in Q3 2026, serving as a key stock catalyst [12] - The phase II RESTORE study for ALD began in July 2025, with enrollment challenges noted [13] Strategic Positioning - ALT's multi-indication potential for pemvidutide, along with the clustering of 2026 catalysts, positions the company as a potential licensing or takeover candidate [14] - Regulatory designations, including FDA Fast Track and Breakthrough Therapy Designation for MASH and AUD, underscore the significance of these indications [15] Financial Considerations - The investment thesis highlights strong phase II results, a differentiated dual-pathway approach, and a robust 2026 calendar with multiple catalysts [16] - ALT anticipates needing additional capital to fund phase III trials, with rising cash usage expected in 2026 [18]

Core Insights - Altimmune (ALT) is focusing on pemvidutide as the central element of its equity story, targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) with a balanced 1:1 glucagon/GLP-1 dual receptor agonist [1] Company Developments - The company has no product revenue base, leading to stock trading based on clinical execution and funding optics, with significant milestones expected in 2026 [2] - ALT plans to initiate a global phase III program in MASH in 2026, aiming for accelerated approval based on biopsy co-primary endpoints [3] - The phase II RECLAIM study for AUD is expected to yield top-line data in Q3 2026, which is seen as a key catalyst for the stock [5][6] - Enrollment for the phase II RESTORE study in ALD is anticipated to complete later in 2026, with challenges noted in patient recruitment [4][8] Financial Position - Altimmune ended 2025 with $274 million in cash, which increased to approximately $340 million by late February 2026 following a $75 million direct offering [10] - The company has access to a $125 million credit facility and projects a cash runway into 2028, although additional funding will likely be needed as phase III spending increases [12][11] Competitive Landscape - Pemvidutide faces competition in AUD from approved options like Vivitrol and generics such as naltrexone and acamprosate, as well as newer approaches under development [7] - In MASH, the competitive landscape includes GLP-1 drugs and other therapies, with major players like Novo Nordisk and Eli Lilly actively involved [15] - The ALD market also features various development activities, including FGF-21 and GLP-1 approaches, indicating a crowded competitive environment [16]

Core Insights - Altimmune (ALT) is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited [1] - The key question for investors is whether pemvidutide's dual-pathway biology and tolerability profile can hold up as ALT moves from encouraging mid-stage data into pivotal execution [1] ALT's Pipeline-in-a-Product Thesis - Pemvidutide is designed as a balanced 1:1 glucagon/GLP-1 dual receptor agonist, addressing metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) with one core drug platform [2] - The thesis pairs a liver-directed mechanism with a weight-loss pathway, targeting multiple disease drivers rather than treating a single dimension of MASH biology [3] Altimmune's Dual Pathway Rationale - ALT's strategy utilizes two hormone pathways that may complement each other in liver disease, with glucagon working directly on the liver to reduce liver fat, inflammation, and scarring [4] - GLP-1 is associated with appetite reduction and weight loss, and combining glucagon's liver effects with GLP-1's metabolic impact could address multiple aspects of liver disease [5] ALT's EuPort Design and Tolerability Angle - Pemvidutide incorporates ALT's proprietary EuPort technology to slow absorption, aiming for improved tolerability by reducing common gastrointestinal side effects [7] - Better tolerability can support longer treatment duration and adherence, which is crucial in chronic liver diseases [8] Altimmune's Phase IIb MASH Readout Takeaways - In the phase IIb MASH program, pemvidutide showed statistically significant MASH resolution without worsening fibrosis at 24 weeks, with durability reported through 48 weeks [9] - Non-invasive markers of fibrosis significantly improved versus placebo, and weight loss was reported in the higher-dose group [10] ALT's Phase III Setup and What FDA Alignment Signals - ALT plans to initiate a global phase III MASH study in 2026, focusing on patients with moderate-to-severe liver fibrosis, designed to support accelerated approval [11] - The study will involve approximately 1,800 patients, with management securing manufacturing supply for the global phase III study [12] - FDA alignment on key late-stage parameters, along with Breakthrough Therapy Designation in MASH, strengthens the regulatory posture heading into pivotal execution [13]

Core Insights - Altimmune, Inc. (NASDAQ:ALT) is recognized as one of the top 10 stocks under $5 with potential for significant growth [1] - H.C. Wainwright has raised the price target for Altimmune from $12 to $25, maintaining a "Buy" rating, reflecting optimism around the company's pipeline expansion [2] - The focus on the MASH program and the potential of pemvidutide for treating alcohol-related liver disease are highlighted as key drivers for investment [3] Group 1: Company Overview - Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics, including pemvidutide for obesity and NASH, and HepTcell for hepatitis B [5] Group 2: Market Outlook - Analysts at B. Riley noted the differentiation of pemvidutide as it enters Phase 3 trials and highlighted a $340 million pro-forma cash runway, which supports a positive outlook for the company [4] - The upcoming Phase 2 RECLAIM AUD topline data expected in Q3 2026 is also a significant factor in the company's future prospects [4]

Group 1 - The company has made significant progress in clinical trials, particularly with the Phase II MASH trial, which provided data at both 24 weeks and 48 weeks [2] - The 48-week data set reinforces expectations for the upcoming Phase III trial design for pemvidutide in MASH [2] - The company anticipates an exciting year ahead in 2026, indicating ongoing developments and potential advancements [2]

Summary of Altimmune's Conference Call Company Overview - **Company**: Altimmune - **Key Executives Present**: Jerry Durso (CEO), Christophe Arbet-Engels (CMO), Greg Weaver (CFO) [1][2] Industry and Product Focus - **Industry**: Biotech, specifically focusing on liver diseases such as Metabolic Associated Steatotic Hepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) - **Key Product**: Pemvidutide, a dual-action drug targeting glucagon and GLP-1 receptors [4][12] Key Highlights and Core Points Clinical Progress - **MASH Trials**: Significant progress in the Phase 2 MASH trial with 24-week and 48-week data showing potential for pemvidutide as a differentiated product in the MASH space [4][5] - **AUD Trials**: Enrollment ahead of schedule with top-line data expected in Q3 2026 [8] - **ALD Trials**: Enrollment expected to complete this year with two main readouts at 24 weeks and 48 weeks [43] Financial Position - **Balance Sheet**: Focus on strengthening the balance sheet through a combination of debt and equity, with discussions ongoing with strategic partners [6] - **Capital Allocation**: Emphasis on ensuring sufficient capital for the Phase 3 trial initiation [6] Differentiation of Pemvidutide - **Mechanism of Action**: Unique one-to-one ratio of glucagon and GLP-1, showing strong effects on fibrosis and MASH resolution [12] - **Tolerability**: Lower discontinuation rates compared to competitors, with a focus on preserving lean mass during weight loss [12][13] - **Data Insights**: Positive 48-week data indicating a clear dose response and strong anti-fibrotic effects [19] Phase 3 Trial Design - **Trial Structure**: Three arms including placebo and two doses (1.8 mg and 2.4 mg), with a focus on good tolerability observed in Phase 2 [22] - **Use of AIM-MASH AI Assist**: A novel tool to reduce variability in histology readings and improve objectivity in trial outcomes [26][29] Regulatory Considerations - **FDA Discussions**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) as endpoints, with current data being captured for potential future discussions [35] Market Potential - **AUD Population**: Estimated 12 million individuals in the AUD category, with a significant unmet need for effective treatments [50] - **Pricing Strategy**: Anticipation of different pricing strategies for MASH and AUD therapies, with a focus on differentiation and value [52][53] Additional Insights - **Enrollment Timelines**: Expectation to complete enrollment for trials within 18-24 months, leveraging strong site relationships and previous trial learnings [38] - **Patient-Reported Outcomes**: Emphasis on capturing both subjective and objective measures of treatment efficacy in AUD trials [40][41] Conclusion - Altimmune is positioned for a significant year ahead with multiple ongoing trials and a focus on innovative treatment approaches for liver diseases, particularly through the development of pemvidutide. The company is actively working on strengthening its financial position and preparing for Phase 3 trials while engaging with regulatory bodies to optimize trial outcomes and market entry strategies.

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Event**: Leerink Partners Global Healthcare Conference - **Key Participants**: CEO Jerry Durso, CMO Christophe Arbet-Engels, CFO Greg Weaver Industry Focus - **Primary Focus**: MASH (Metabolic Associated Steatotic Liver Disease) - **Clinical Trials**: Phase 2 and Phase 3 trials for pemvidutide, a treatment for MASH and other liver-related diseases Key Points and Arguments Clinical Data and Regulatory Progress - **2025 Highlights**: Significant clinical data expected, including two readouts from the Phase 2 MASH trial in 2025, with 24-week and 48-week data showing promising results for pemvidutide [6][18] - **Regulatory Feedback**: Received breakthrough therapy designation from the FDA, indicating strong alignment on Phase 3 trial design [6][34] - **Phase 3 Trial**: Focus on a 52-week endpoint to assess antifibrotic effects, with a simple titration scheme for dosing to improve tolerability [20][27] Pemvidutide Differentiation - **Mechanism of Action**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, which is believed to provide a balanced therapeutic effect, unlike competitors like survodutide, which has a 7:1 ratio favoring GLP-1 [10][12] - **Tolerability**: Pemvidutide shows lower discontinuation rates compared to other treatments, with less than placebo rates of discontinuation [13][33] - **Efficacy**: Strong indications of antifibrotic effects observed in non-invasive tests, with confidence in achieving significant results in the upcoming Phase 3 trial [18][19] Market Position and Strategy - **Patient Segmentation**: Physicians are expected to segment patients based on tolerability and efficacy, with pemvidutide positioned as a favorable option for patients who struggle with other incretin therapies [63][64] - **Combination Therapy Potential**: Pemvidutide may serve as a complementary agent in combination therapies, enhancing efficacy without increasing side effects [58][59] Upcoming Trials and Endpoints - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Two unique Phase 2 programs are underway, targeting large unmet needs in these areas [67][68] - **Endpoints for AUD**: Focus on reducing heavy drinking days, with a target of a 1-day reduction in average heavy drinking days as a meaningful clinical outcome [75][77] Regulatory Considerations - **FDA Engagement**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) for regulatory approval, with potential for evolving acceptance during the trial [42][46] - **Global Alignment**: Efforts to align with European regulatory bodies (EMA, MHRA) to ensure a cohesive global strategy for pemvidutide [51] Additional Important Insights - **Long-term Market Outlook**: The MASH market is expected to evolve similarly to the diabetes market, with multiple mechanisms and treatment options becoming available [65] - **Focus on F4 Population**: While the primary focus remains on F2 and F3 populations, there is potential for future exploration in the F4 compensated cirrhotic population [54] This summary encapsulates the critical insights and strategic directions discussed during the Altimmune conference call, highlighting the company's focus on advancing pemvidutide as a leading treatment option in the MASH and liver disease landscape.

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune (NasdaqGM:ALT) - **Event**: Citizens Life Sciences Conference on March 10, 2026 - **Key Speakers**: Jerry Durso (CEO), Linda Richardson (Chief Commercial Officer), Greg Weaver (CFO) Core Industry and Product Insights - **Lead Product**: Pemvidutide, targeting multiple liver indications, primarily MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [4][5] - **Phase 2 Trials**: - Positive results from 24-week and 48-week readouts, showing significant impact on MASH resolution and good tolerability [6][10] - Weight loss and trends on fibrosis were noted, although the fibrosis endpoint was not met due to a high placebo response [7][14] - **Phase 3 Trial Plans**: - Anticipated initiation in 2026 with a focus on a 52-week endpoint and a cohort of nearly 1,000 patients [9][18] - Inclusion of a titration scheme to improve tolerability and patient retention [12][26] Mechanism of Action - **Dual Mechanism**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, aiming to address both liver fat reduction and metabolic effects [28][29] - **Differentiation**: The one-to-one ratio is believed to enhance tolerability and efficacy compared to other glucagon/GLP-1 combinations [29][41] Market Position and Competitive Landscape - **Market Need**: High unmet need in the MASH space, with increasing recognition from physicians and payers [56][60] - **Competitors**: Other GLP-1 therapies and FGF21s are noted, with pemvidutide expected to have a competitive edge due to its unique profile [62][53] - **Commercial Strategy**: Focus on maintaining tolerability and addressing weight loss, which is critical for MASH patients [38][61] Financial Position - **Cash Position**: Strong balance sheet with a runway into 2028, having raised approximately $300 million over the past year [78] - **Strategic Funding**: Open to potential partnerships, especially for ex-US markets [79] Additional Insights - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Ongoing studies with anticipated readouts in 2026, highlighting the potential of pemvidutide in these areas [66][67] - **Market Research**: Indications that current therapies are not meeting weight loss needs, positioning pemvidutide favorably [60][61] Conclusion - Altimmune is poised to advance pemvidutide through its upcoming phase 3 trials, with a strong focus on addressing the significant unmet needs in liver disease management and maintaining a competitive edge in the evolving therapeutic landscape. The company is actively preparing for commercialization while ensuring a robust financial foundation to support its initiatives.

Core Insights - The CEO of Altimmune, Durso Jerome Benedict, purchased 20,000 shares at approximately $3.54 per share, increasing his total holdings to 32,500 shares, indicating strong confidence in the company's future [1][5] - Altimmune is preparing for a pivotal Phase 3 program for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), which aligns with the company's strategic focus on liver disease treatments [2][5] - The unique approach of pemvidutide, featuring "balanced one-to-one agonism of glucagon and GLP-1," may differentiate Altimmune in the treatment landscape, potentially reducing liver fat and aiding in weight loss [3][5] Financial Overview - The current stock price of ALT is $3.54, with a slight increase of 0.99% or $0.035, and has fluctuated between $3.41 and $3.74 throughout the day [4] - Over the past year, ALT reached a high of $7.73 and a low of $2.9, with a market capitalization of approximately $312.4 million and a trading volume of 5,385,353 shares [4]

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024 [31][32] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the end of the phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by a one-time charge related to executive transition [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from phase 2 trials indicating strong therapeutic potential [6][9] - The phase 2 MASH study showed early resolution at 24 weeks and anti-fibrotic activity at 48 weeks, with significant improvements in liver fat and inflammation markers [9][17] Market Data and Key Metrics Changes - Market research indicated a high unmet need for therapies addressing tolerability issues in MASH patients, with many physicians seeking alternatives to existing treatments [25][26] - Over 70% of healthcare professionals surveyed expressed a high likelihood of prescribing pemvidutide, indicating strong market interest [28] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and clinical development [11] - The phase 3 trial for pemvidutide is set to begin this year, with a focus on addressing both hepatic and metabolic drivers of MASH [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide, especially after receiving FDA Breakthrough Therapy designation for MASH [10] - The company is preparing for the phase 3 trial while ensuring financial stability, with a cash position of approximately $340 million expected to support operations into 2028 [33][34] Other Important Information - The company has received valuable guidance from the FDA regarding the phase 3 trial design, which will include both biopsy-confirmed and non-invasive test cohorts [20][22] - The phase 2 trials for AUD and ALD are progressing well, with top-line data expected from the AUD trial in Q3 2026 [23][24] Q&A Session Summary Question: Can the FDA's new single pivotal framework save costs for the phase 3 trial? - Management indicated that the current approach remains unchanged and the single trial path for accelerated approval is still valid [38] Question: What are the statistical plans for the phase 3 trial? - The phase 3 trial is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [41] Question: What is the FDA's stance on using non-invasive tests as registrational endpoints? - The FDA deemed it premature to consider non-invasive tests for approval, focusing instead on biopsy-driven endpoints [48] Question: What are the key elements locked in for the phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, while ensuring comprehensive biopsy processes [85] Question: How will the company approach the AUD and ALD trials? - The company plans to assess AUD data and make decisions without waiting for ALD results, focusing on immediate next steps [93]